NVS ▼ -8.0% - Novartis AG $NVS says Phase 3 trial for Cardiovascular disease did not meet primary endpoint Novartis shares fell 8.0% after the company announced that a Phase 3 trial for its cardiovascular disease treatment failed to meet its primary endpoint. The failed trial outcome removes a potential revenue driver from the company's pipeline and raises questions about the viability of the program. 04-SEP-2026 04:33 PM ET